Lincoln, Nebraska, Jan. 30, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ/:NRC) today announced that it will provide an online web simulcast of its 2022 fourth quarter earnings conference call on Wednesday, February 15, 2023. The Company’s results for the 2023 fourth quarter will be released after the close of the market on Tuesday, February 14, 2023.
The live broadcast of National Research Corporation’s conference call will begin at 11:00 a.m. Eastern Time on February 15, 2023. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
A live audio webcast can be accessed at https://events.q4inc.com/attendee/759565253. The webcast will also be available for replay.
For more than 40 years, NRC Health has been committed to achieving Human Understanding and bringing healthcare oreganizations closer to their customers than ever before by illuminating and improving the key moments that define an experience and build trust. Gided by their uniquely empathic heritage, proprietary methods, skilled associates, and holistic approach, NRC Health helps its customers design experiences that exceed expectations inspire loyalty, and improve well-being among patients, residents, physicians, nurses, and staff. For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it., or visit www.nrchealth.com
Last Trade: | US$10.54 |
Daily Change: | 0.01 0.09 |
Daily Volume: | 80,500 |
Market Cap: | US$247.480M |
February 25, 2025 January 27, 2025 October 25, 2024 August 22, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load